Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific has launched a docuseries campaign ... “I was dry right away, immediately, from the moment we activated to when I got home and since. No longer do I have to worry about ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

Shares of Boston Scientific Corp. BSX inched 0.97% higher to $85.54 Tuesday, on what proved to be an all-around positive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor. It is projected by analysts that the 'Net Sales ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

The best home security systems provide comfort and confirmation that your abode is always protected—whether that means that you monitor the situation through a phone app or the monitoring is ...

Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported basis and 15% on an organic basis, compared to prior guidance of 13.5%-14.5% and 13%-14% ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...